- RecruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Austria - Active not recruitingPHASE1
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
This study is testing a new drug called Bleximenib alongside standard treatments for acute myeloid leukaemia (AML). It aims to find the safest and most effective dose of Bleximenib when given with other AML medicines, and to understand its side effects.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Canada - RecruitingPHASE1
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
This study is testing a new drug, JNJ-90189892, sometimes with other medicines, for adults with acute myeloid leukemia (AML) or certain types of myelodysplastic neoplasms (MDS). It aims to find the safest and most effective doses for these blood cancers.
For: Leukemia, Myeloid, Acute · Myelodysplastic NeoplasmsAustralia · France · Spain - RecruitingPHASE2
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
This study looks at combining a new drug, Gilteritinib, with standard treatments (Venetoclax and Azacitidine) for acute myeloid leukaemia (AML) in patients who have a specific gene change (FLT3 mutation) and can't have strong chemotherapy. It aims to find the safest and most effective dose.
For: AML - Acute Myeloid LeukemiaGermany